BioXcel Therapeutics, Inc. submitted a supplemental New Drug Application on January 14, 2026, to the FDA for IGALMI® to be used at home for treating agitation related to bipolar disorders or schizophrenia. This seeks to expand its existing approval for use only under healthcare supervision, highlighting a new treatment option for patients.